|Publication number||US7233822 B2|
|Application number||US 10/881,541|
|Publication date||Jun 19, 2007|
|Filing date||Jun 29, 2004|
|Priority date||Jun 29, 2004|
|Also published as||CA2567871A1, EP1784127A1, US20050288725, WO2006004700A1|
|Publication number||10881541, 881541, US 7233822 B2, US 7233822B2, US-B2-7233822, US7233822 B2, US7233822B2|
|Inventors||Douglas A. Hettrick, David E. Euler, Mark L Brown|
|Original Assignee||Medtronic, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (33), Non-Patent Citations (1), Referenced by (4), Classifications (29), Legal Events (3)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The present invention relates generally to implantable cardiac stimulation and monitoring devices and particularly to a device and method for detecting and classifying arrhythmias using intracardiac pressure information.
In the past, atrial arrhythmias have been largely undertreated due to the perception that these arrhythmias are relatively benign. As more serious consequences of persistent atrial fibrillation have come to be understood, such as an associated risk of relatively more serious ventricular arrhythmias and stroke, there is a greater interest in providing implantable atrial or dual chamber cardioverter defibrillators for treating atrial arrhythmias.
Atrial fibrillation (AF) can be treatable with relatively high voltage defibrillation shocks, which are generally painful to the patient, or high frequency pulse bursts. Atrial flutter (AFL), also referred to herein as atrial tachycardia (AT) can be treated by anti-tachycardia pacing (ATP) therapies, pulse bursts or cardioversion shocks. Generally, it is preferred to initially treat AFL with a less aggressive therapy such as ATP, which is not painful to the patient and requires less battery energy than cardioversion shocks. Reliable discrimination between AFL and AF is important in selecting the appropriate atrial arrhythmia therapy and is also useful in monitoring a patient's arrhythmia disease status, managing medical therapy, and evaluating the effectiveness of arrhythmia therapies.
In AFL, the atria beat at an elevated rate that is highly regular, typically at 200 to 320 beats per minute. While beating at a pathologically high rate, the atrial contraction can be sufficiently coordinated to generate pressure within the atria. In AF, the atria depolarize at an elevated rate that can be regular or irregular. The atrial contraction is disorganized, however, and not efficient enough to generate pressure. AFL, characterized by a single depolarizing wavefront, is often treatable by anti-tachycardia pacing (ATP) therapies, whereas AF, characterized by multiple depolarizing wavefronts, is not treatable by ATP therapies.
Clinically, the efficacy of atrial ATP therapies is reportedly, on the order of less than 50%. This low efficacy rate may not reflect the effectiveness of atrial ATP therapies in successfully treating AFL, but instead reflect inappropriate AFL detections resulting in the delivery of atrial ATP therapies during a rhythm that is untreatable by ATP. If the rhythm is in fact AF, atrial ATP therapies will be ineffective. On the other hand, arrhythmias classified as AF that are in fact fast AFL may be unnecessarily treated with a more aggressive arrhythmia therapy such as a shock therapy, needlessly exposing the patient to shock pain and consuming battery energy. Improved specificity of atrial arrhythmia classification methods may therefore allow ATP therapy efficacy to be improved and conservative but appropriate use of defibrillation shock therapies.
Methods for specifically classifying atrial arrhythmias, for monitoring or therapy selection purposes, generally depend only on atrial rate information in current commercially available devices. Such information may include the atrial rate and the regularity of the atrial rate. A range of atrial rates may be specified for detecting AFL and a different, generally higher, range of atrial rates may be specified for detecting AF. However, because the atrial rate could be the same during AFL and AF, specified ranges for AFL and AF detection may overlap and therefore rate information alone is not always adequate for detecting and discriminating AFL and AF. When an atrial rate is detected in this overlap range, atrial cycle length regularity may be used for discriminating between AFL and AF. However, because the atrial cycle length can be regular during AF in some patients, atrial cycle length regularity may not always be a dependable distinguishing factor in discriminating AFL from AF either.
Therefore, what is needed is a method and device for discriminating between atrial arrhythmias when atrial rate information is ambiguous in discriminating AFL from AF.
Aspects of the present invention will be readily appreciated as they become better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:
The present invention provides a system and method for detecting and classifying cardiac arrhythmias based on cardiac electrical and pressure signals. The method includes sensing an EGM signal to derive a cardiac rate; detecting an arrhythmia when the cardiac rate meets arrhythmia detection criteria; sensing an intracardiac pressure signal to derive an indicator of tachycardia; classifying the detected arrhythmia based on the sensed pressure signal wherein the derived indicator of tachycardia is compared to tachycardia detection criteria and the arrhythmia is classified as tachycardia if tachycardia detection criteria are met and the arrhythmia is classified as fibrillation if the tachycardia detection criteria are not met.
In one embodiment, an atrial EGM signal and an atrial pressure signal are sensed for the detection and classification of atrial arrhythmias. An indicator of atrial tachycardia, referred to herein as atrial flutter or “AFL,” is derived from the atrial pressure signal using time-domain or frequency-domain signal analysis. An indicator of AFL determined using time-domain signal analysis methods may be an integral, a peak magnitude, average peak magnitude, average magnitude or other feature of the high frequency signal content, which, if greater than a predetermined AFL detection threshold value, indicates the presence of AFL. In other embodiments, an AFL indicator may be based on a correlation of gated signal averages or other indices of atrial pressure amplitude variability.
In embodiments employing frequency-domain signal analysis methods, and AFL indicator may be determined as an unexpected peak at a non-harmonic frequency of the underlying ventricular rate or as a comparative index of the low and high frequency magnitudes of a Fourier transform of the atrial pressure signal, e.g., a peak magnitude ratio, an average magnitude ratio, summed magnitude ratio, or magnitude difference, which may be compared to a predetermined AFL detection threshold value.
The present invention is realized in an implantable system including a cardiac stimulation or monitoring device and associated leads equipped with electrodes for sensing the cardiac EGM signal and a pressure sensor for sensing intracardiac pressure. The device includes sensor interfaces and signal processing circuitry for determining cardiac rate related information from the EGM signal and pressure information from the pressure signal. A control unit executes arrhythmia detection methods for detecting an arrhythmia based on rate information and classifying the arrhythmia based on pressure information. The device may include a therapy delivery unit for applying therapeutic electrical stimulation to the heart. An arrhythmia detection and classification made using the methods included in the present invention may be used for selecting and initiating an arrhythmia therapy.
In dual or multichamber systems, the cardiac stimulation device may additionally be capable of sensing ventricular signals and delivering ventricular arrhythmia therapies and may provide bradycardia pacing or other types of cardiac stimulation therapies. While the present invention is expected to be particularly beneficial in discriminating AFL from AF, the invention may also be beneficial in discriminating ventricular arrhythmias, e.g., ventricular tachycardia from ventricular fibrillation. Furthermore, aspects of the present invention for detecting and classifying arrhythmias may be implemented in a cardiac monitoring device without having arrhythmia therapy delivery capabilities. However, to illustrate the benefits of the present invention, the preferred embodiments described herein relate to a dual chamber implantable cardioversion defibrillation device.
Device 10 of
The right atrial lead 15 is positioned such that its distal end is in the right atrium. Lead 15 is equipped with a ring electrode 21 and a tip electrode 17 for sensing and pacing in the right atrium. Lead 15 is further equipped with a superior vena cava (SVC) coil electrode 23 for delivering high-energy shock therapy. The ring electrode 21, the tip electrode 17 and the SVC coil electrode 23 are each connected to an insulated conductor with the body of the right atrial lead 15. Each insulated conductor is coupled at its proximal end to a connector carried by a connector assembly.
In accordance with the present invention, right atrial lead 15 is further equipped with a pressure sensor 19 for sensing right atrial pressure. Pressure sensor 19 may be embodied as generally disclosed in commonly-assigned U.S. Pat. Nos. 5,535,752 and 5,564,434, incorporated by reference herein in their entireties. Alternatively, pressure sensor 19 may be embodied as generally described in U.S. Pat. No. 5,324,326 issued to Lubin, incorporated herein by reference in its entirety, or any other pressure sensing modules adapted for sensing intra-cardiac pressure. While the embodiment shown in
The electrodes 17 and 21 or 24 and 26 may be used as bipolar pairs, commonly referred to as a “tipto-ring” configuration, or individually in a unipolar configuration with the device housing 11 serving as the indifferent electrode, commonly referred to as the “can” or “case” electrode. The device housing 11 may also serve as a subcutaneous defibrillation electrode in combination with one or more of the defibrillation coil electrodes 20 or 23 for defibrillation of the atria or ventricles. It is recognized that alternate lead systems may be substituted for the lead system illustrated in
With regard to the electrode system illustrated in
The connection terminals 317 and 321 provide electrical connection to tip electrode 17 and ring electrode 21 positioned in the right atrium. The connection terminals 317 and 321 are further coupled to an atrial sense amplifier 204 for sensing atrial signals such as P-waves. The connection terminals 326 and 324 provide electrical connection to tip electrode 26 and the ring electrode 24 positioned in the right ventricle. The connection terminals 326 and 324 are further coupled to a ventricular sense amplifier 200 for sensing ventricular signals.
The atrial sense amplifier 204 and the ventricular sense amplifier 200 preferably take the form of automatic gain controlled amplifiers with adjustable sensing thresholds. The general operation of the ventricular sense amplifier 200 and the atrial sense amplifier 204 may correspond to that disclosed in U.S. Pat. No. 5,117,824, by Keimel, et al., incorporated herein by reference in its entirety. Whenever a signal received by atrial sense amplifier 204 exceeds an atrial sensing threshold, a signal is generated on the P-out signal line 206. Whenever a signal received by the ventricular sense amplifier 200 exceeds a ventricular sensing threshold, a signal is generated on the R-out signal line 202.
Switch matrix 208 is used to select which of the available electrodes are coupled to a wide band amplifier 210 for use in digital signal analysis. Selection of the electrodes is controlled by the microprocessor 224 via data/address bus 218. The selected electrode configuration may be varied as desired for the various sensing, pacing, cardioversion and defibrillation functions of the ICD 10. Signals from the electrodes selected for coupling to bandpass amplifier 210 are provided to multiplexer 220, and thereafter converted to multi-bit digital signals by A/D converter 222, for storage in random access memory 226 under control of direct memory access circuit 228. Microprocessor 224 may employ digital signal analysis techniques to characterize the digitized signals stored in random access memory 226 to recognize and classify the patient's heart rhythm based on EGM information employing any of the numerous signal processing methods known in the art. As will be described further below, microprocessor 224 may additionally employ signal analysis techniques for evaluating an atrial pressure signal for using in classifying the patient's heart rhythm.
Device 10 further includes a pressure sensor interface 331 for receiving and processing a pressure signal received at terminal 318 from pressure sensor 19. Pressure sensor interface 334 may include various filters, amplifiers, and/or other circuitry for conditioning a pressure signal, in this embodiment a right atrial pressure signal. A right atrial pressure signal (or other intracardiac pressure signal) may be converted to a digital signal by A/D converter 222 for further signal processing by microprocessor 224.
The telemetry circuit 330 receives downlink telemetry from and sends uplink telemetry to an external programmer, as is conventional in implantable cardiac stimulation devices, by means of an antenna 332. Received telemetry is provided to microprocessor 224 via multiplexer 220. Data to be uplinked to the programmer and control signals for the telemetry circuit 330 are provided by microprocessor 224 via address/data bus 218. Data to be uplinked may include a record of detected and classified arrhythmia episodes as is customary in modern implantable cardioverter defibrillators. Numerous types of telemetry systems known for use in implantable devices may be used.
The remainder of circuitry illustrated in
During pacing, escape interval counters within pacer timing and control circuitry 212 are reset upon sensing of R-waves or P-waves as indicated by signals on lines 202 and 206, respectively. In accordance with the selected mode of pacing, pacing pulses are generated by atrial pacer output circuit 214 and ventricular pacer output circuit 216. The pacer output circuits 214 and 216 are coupled to the desired electrodes for pacing via switch matrix 208. The escape interval counters are reset upon generation of pacing pulses, and thereby control the basic timing of cardiac pacing functions, including anti-tachycardia pacing.
The durations of the escape intervals are determined by microprocessor 224 via data/address bus 218. The value of the count present in the escape interval counters when reset by sensed R-waves or P-waves can be used to measure R—R intervals, P—P intervals, P–R intervals, and R–P intervals, which measures are stored in memory 226 and for use in diagnosing the occurrence of a variety of arrhythmias.
Microprocessor 224 operates as an interrupt driven device and is responsive to interrupts from pacer timing and control circuitry 212 corresponding to the occurrences of sensed P-waves and R-waves and corresponding to the generation of cardiac pacing pulses. Any necessary mathematical calculations to be performed by microprocessor 224 and any updating of the values or intervals controlled by pacer timing/control circuitry 212 take place following such interrupts. A portion of the random access memory 226 may be configured as a number of recirculating buffers capable of holding a series of measured intervals, which may be analyzed in response to a pace or sense interrupt by microprocessor 224 for diagnosing an arrhythmia. Any of the various arrhythmia detection methodologies known to the art may be employed in conjunction with the present invention for detecting and classifying arrhythmias.
In response to the detection of atrial flutter or ventricular tachycardia, an ATP therapy may be delivered if desired by loading a regimen from microcontroller 224 into the pacer timing and control circuitry 212 according to the type of tachycardia detected. Alternatively, circuitry for controlling the timing and generation of anti-tachycardia pacing pulses as generally described in U.S. Pat. No. 4,577,633 issued to Berkovits et al., U.S. Pat. No. 4,880,005 issued to Pless et al., U.S. Pat. No. 4,726,380 issued to Vollmann et al., and U.S. Pat. No. 4,587,970 issued to Holley et al, all of which patents are incorporated herein by reference in their entireties, may be used.
In the event that higher voltage cardioversion or defibrillation shock pulses are required, microprocessor 224 activates the cardioversion and defibrillation control circuitry 230 to initiate charging of the high voltage capacitors 246 and 248 via charging circuit 236 under the control of high voltage charging control line 240. The voltage on the high voltage capacitors 246 and 248 is monitored via a voltage capacitor (VCAP) line 244, which is passed through the multiplexer 220. When the voltage reaches a predetermined value set by microprocessor 224, a logic signal is generated on the capacitor full (CF) line 254, terminating charging. Thereafter, timing of the delivery of the defibrillation or cardioversion pulse is controlled by pacer timing and control circuitry 212.
One embodiment of an appropriate system for delivery and synchronization of ventricular cardioversion and defibrillation pulses and for controlling the timing function related to them is generally disclosed in commonly assigned U.S. Pat. No. 5,188,105 to Keimel, incorporated herein by reference in its entirety. If atrial defibrillation capabilities are included in the device, appropriate systems for delivery and synchronization of atrial cardioversion and defibrillation pulses and for controlling the timing function related to them may be found in U.S. Pat. No. 4,316,472 issued to Mirowski et al., U.S. Pat. No. 5,411,524 issued to Mehra, or U.S. Pat. No. 6,091,988 issued to Warman. Any known ventricular cardioversion or defibrillation pulse control circuitry may be usable in conjunction with the present invention. For example, circuitry controlling the timing and generation of cardioversion and defibrillation pulses as disclosed in U.S. Pat. No. 4,384,585, issued to Zipes, U.S. Pat. No. 4,949,719, issued to Pless et al., and in U.S. Pat. No. 4,375,817, issued to Engle et al., may be used in a device employing the present invention.
In the illustrated device, delivery of cardioversion or defibrillation pulses is accomplished by output circuit 234, under control of control circuitry 230 via control bus 238. Output circuit 234 determines the shock pulse waveform, e.g. whether a monophasic, biphasic or multiphasic pulse is delivered, whether the housing 311 serves as cathode or anode, which electrodes are involved in delivery of the pulse, and the pulse shape and tilt. Examples of high-voltage cardioversion or defibrillation output circuitry are generally disclosed in U.S. Pat. No. 4,727,877 issued to Kallok, and U.S. Pat. No. 5,163,427 issued to Keimel, incorporated herein by reference in their entireties.
In modern implantable cardioverter defibrillators, the particular therapies are programmed into the device ahead of time by the physician, and a menu of therapies is typically provided. For example, on initial detection of tachycardia, an ATP therapy may be selected. On redetection of tachycardia, a more aggressive ATP therapy may be scheduled. If repeated attempts at ATP therapies fail, a higher-level cardioversion pulse therapy may be selected thereafter. As in the case of currently available ICDs, and as discussed in the above-cited references, the amplitude of the defibrillation shock may be incremented in response to failure of an initial shock or shocks to terminate fibrillation. Prior art patents illustrating such pre-set therapy menus of anti-tachycardia therapies include the above-cited U.S. Pat. No. 4,726,380 issued to Vollmann et al., above cited U.S. Pat. No. 4,587,970 issued to Holley et al., and U.S. Pat. No. 4,830,006 issued to Haluska, incorporated herein by reference in their entirety.
At block 355, the atrial EGM signal is sensed using one or both of right atrial tip and ring electrodes 17 and 21. At block 360, the atrial rate is determined from the sensed EGM signal. The atrial rate may be determined based on P—P intervals according to methods known in the art. At decision block 365, microprocessor 224 determines if the atrial rate meets arrhythmia detection criteria. Typically, a predefined number of P—P intervals out of a given number of consecutive P—P intervals must be equal to or less than an arrhythmia detection interval. Arrhythmia detection intervals may be defined according to AFL and AF “zones” wherein the AFL detection intervals include one range of P—P intervals and AF detection intervals include a different range of P—P intervals that are typically shorter than the AFL detection intervals. The AFL and AF detection zones may, however, overlap.
In one embodiment, atrial pressure sensing is enabled, block 370, if a high atrial rate is detected regardless of whether the rate falls within the AFL, AF or overlap zone. In other embodiments, atrial pressure sensing may be enabled, block 370, only if the atrial rate falls within the overlap zone to provide an additional parameter to discriminate between AFL and AF when rate information alone is ambiguous.
It is further recognized that atrial pressure sensing may be enabled prior to rate-related arrhythmia detection criteria being satisfied. For example, atrial pressure sensing may be enabled as soon as a predefined number of one or more fast P—P intervals are sensed rather than waiting for rate-related arrhythmia detection criteria to be satisfied.
At block 375, the atrial pressure signal is analyzed to determine if the frequency content of the pressure signal indicates the presence of AFL. Methods for evaluating the atrial pressure signal for indicators of AFL will be described in detail below. Such indicators relate to the atrial contribution to the measured pressure signal. If the atrial pressure signal indicates the presence of AFL, AFL is detected at block 385. If the atrial pressure signal does not indicate the presence of AFL, AF is detected at block 380. The arrhythmia detection and classification made at block 380 or 385 may be used to trigger an appropriate arrhythmia therapy or menu of therapies. For example, the detection of AFL may trigger ATP therapy delivery whereas an AF detection may trigger a defibrillation shock.
The AF or AFL episode detection and the duration of the episode may be logged in device memory, as is conventional in implantable cardioverter defibrillator devices, such that a history of detected arrhythmias is available to a physician. The improved accuracy of atrial arrhythmia classifications made based on pressure monitoring provides more specific and accurate data regarding the number and duration of AFL and AF episodes, improving the utility of the device reported diagnostics.
As such, it is desirable to update the atrial rhythm classification on a continuous or periodic basis during a sustained AFL/AF detection since the rhythm may transition between AF and AFL during a single episode. Such transitions are important to detect for both monitoring and data storage and for therapy selection purposes. Therefore, after initially classifying an atrial arrhythmia as AF or AFL at blocks 380 or 385, respectively, the method shown in
Ventricular pressure monitoring is also contemplated for use in deriving an indicator of AFL. A ventricular pressure signal is similar to the atrial pressure signal during the ventricular filling phase of the cardiac cycle. Therefore, a pressure sensor positioned in the right or left ventricle may be used to obtain a ventricular pressure signal. The signal obtained during the ventricular filling phase may undergo signal processing for deriving an indicator of AFL that relates to the atrial contribution to the ventricular pressure signal during the filling phase.
As shown in
The difference in frequency content of the atrial pressure signal during AFL and AF, readily observed in
The output 505 of filter 504 is provided as the negative input to summing block 506. The output 507 of summing block 506, which is the difference between the raw pressure signal 502 and the filtered signal 504, will contain only the high frequency pressure signal components. This difference output signal 507 is provided as input to rectifier 508, and the rectified signal 509 is integrated by integrator 510. The integrated signal 511 is compared to a predetermined threshold by threshold detector 520. If the integral of the rectified high-frequency signal exceeds a predetermined threshold, AFL is indicated based on a relatively high content of high-frequency signals. If the integral of the high-frequency signal does not exceed a predetermined threshold, AF is indicated. The indication of AFL or AF may be made according to a signal output 522 of threshold detector 520. Thus, in this embodiment, an AFL indicator is determined as the integral of the rectified, high frequency component of the pressure signal.
The integral may be determined over one or more cardiac cycles. Alternatively, an integral of the rectified high frequency component of the pressure signal may be determined over each cardiac cycle for a number of cardiac cycles. The integral for each cardiac cycle may be compared to an AFL detection threshold and AFL may be detected when a predetermined number of cardiac cycle integrals exceed the AFL detection threshold. A threshold value may be set to a nominal value by a physician based on clinical experience, or selected based on measurements of atrial pressure in an individual patient during normal sinus rhythm and/or during episodes of AFL and AF.
The three plots shown on the right in
By comparing high frequency signal 607 during AFL and high frequency signal 617 during AF, it is readily seen that the high frequency signal is of greater energy during AFL than during AF. Numerous methods may be proposed for discriminating between this high frequency energy difference. As proposed above in conjunction with
Alternatively, a maximum or averaged peak amplitude of the high frequency signal may be compared to a predetermined threshold value 620 as shown in
In one method 700, an atrial pressure signal is sampled at block 705 at a sampling rate sufficient to capture the high frequency components that may be present during AFL. At block 710, a summation of all data points sampled during a single cardiac cycle is determined. Cardiac cycle boundaries are preferably determined by sensed R-waves. Alternatively, cardiac cycle boundaries could be determined from the low frequency component of the pressure signal directly (as in
At blocks 720 and 725, a summation of the sampled pressure signal points is determined for each cardiac cycle during the next epoch, l+1, and stored as the gated signal averages at block 725. At block 730, the correlation between the gated signal averages stored during the first epoch, GSA(l), and the gated signal averages stored during the subsequent epoch, GSA(l+1), is determined. If the correlation is approximately 1, i.e. the GSAs during the first epoch are approximately equal to the GSAs during the second epoch, a provisional atrial arrhythmia detection based on atrial rate is classified as AF at block 745. If the correlation is substantially different than 1, for example less than a predetermined value less than 1, a provisionally detected arrhythmia is classified as AFL at block 740. In other embodiments, a standard deviation of the sample point amplitudes or other statistical parameter for measuring pressure wave amplitude variation may be determined as an AFL indicator and compared to a threshold value.
Frequency-domain analyses may alternatively be used for determining if the high-frequency content of an atrial pressure signal is indicative of AFL.
When AFL is present, an unexpected peak may occur at a frequency corresponding to the atrial rate. In the example shown in
Alternatively, an average energy (magnitude) above threshold frequency 800 and an average energy below the threshold frequency 800 may be determined. A ratio of the “high” frequency average energy to the “low” frequency average energy may be compared to an AFL detection threshold. In yet another embodiment, a summed magnitude ratio may be determined as the ratio of the summation of the magnitudes of all peaks above the threshold frequency 800 to the summation of the peak magnitudes below the threshold frequency 800. This summed magnitude ratio may be compared to an AFL detection threshold. If an average energy ratio or a summed magnitude ratio is greater than a predefined AFL detection threshold, a provisionally detected atrial arrhythmia is classified as AFL and otherwise classified as AF.
In still another embodiment, the difference between the dominant peak magnitude 802 below the threshold frequency 800 and the dominant peak magnitude 804 above the threshold frequency 800 may be determined. If this difference is less than an AFL detection threshold, AFL may be detected whereas if the difference is greater than an AFL detection threshold, AF may be detected.
Thus, in a frequency-domain analysis, an AFL indicator may be determined as an unexpected peak at a non-harmonic frequency of the underlying ventricular rate or as a comparative index of the low and high frequency magnitudes, e.g., a peak magnitude ratio, an average magnitude ratio, summed magnitude ratio, or magnitude difference, which may be compared to a predetermined AFL detection threshold value.
As indicated previously, an arrhythmia therapy selection may be based on the AF or AFL classification made according to the methods described herein.
For example, if the rate is in the AF zone but atrial pressure analysis indicates AFL, an ATP therapy may be selected first as a more conservative approach. Alternatively, a defibrillation shock may be selected immediately in a more aggressive approach. The approach taken, more conservative or more aggressive, may depend on individual patient considerations and physician preferences.
A method allowing such therapy selection options to be taken is shown in
After classifying the rhythm as AFL at block 385 based on atrial pressure signal analysis performed at block 375 according to any of the methods described above, a determination is made whether the atrial rate falls in the AFL zone at decision block 387. If the rate is in the AFL zone, a programmed menu of therapies for responding to AFL, typically beginning with ATP, is delivered at block 389. However, if the atrial rate is not in the AFL zone, i.e., the rate is in the AF zone, a therapy may be selected at block 391 in accordance with a previously programmed selection made by the physician. The selected therapy under the circumstances of an atrial rate in the AF zone but atrial pressure signal indicating AFL may be ATP or a defibrillation shock or another selected atrial anti-arrhythmia therapy.
Similarly, after classifying the rhythm as AF at block 380 according to an atrial pressure signal analysis at block 375, a determination is made at decision block 393 whether the atrial rate is in the AF zone, in agreement with the AF classification. If so, the AF may be treated customarily with a defibrillation (DF) shock at block 393. If the atrial rate is not in the AF zone, i.e., the rate is in the AFL zone, a therapy may be selected at block 393 according to a previously programmed selection made by the physician. The selected therapy under this circumstance of an atrial rate in the AFL zone but atrial pressure indicating AF may be ATP, defibrillation shock, or other selected therapy depending on physician preferences and individual patient condition.
Some of the techniques described above may be embodied as a computer-readable medium comprising instructions for a programmable processor such as microprocessor 224 or pacing timing and control 212, for example. The programmable processor may include one or more individual processors, which may act independently or in concert. A “computer-readable medium” includes but is not limited to any type of computer memory such as floppy disks, conventional hard disks, CR-ROMS, Flash ROMS, nonvolatile ROMS, RAM and a magnetic or optical storage medium. The medium may include instructions for causing a processor to perform any of the features described above for initiating a session of the escape rate variation according to the present invention.
It is apparent from the above description that numerous variations and modifications to the methods described herein may be conceived by one having skill in the art and the benefit of the teachings provided herein without departing from the scope of the present invention. A variety of signal processing techniques may be successfully employed by the methods included in the present invention for determining an indicator of AFL based on an evaluation of the frequency content of an atrial pressure signal in the time or frequency domain. The methods described herein for detecting and classifying an arrhythmia based on rate and pressure may be combined with the use of other arrhythmia detection and/or discrimination variables such as rate variability. Furthermore, and as indicated previously, these methods may be adapted for use in classifying ventricular arrhythmias by employing a ventricular pressure signal for discriminating between ventricular tachycardia and fibrillation. The detailed descriptions of the various embodiments provided herein are therefore intended to be exemplary, rather than limiting, with regard to the following claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4316472||Aug 9, 1979||Feb 23, 1982||Mieczyslaw Mirowski||Cardioverting device with stored energy selecting means and discharge initiating means, and related method|
|US4375817||Dec 22, 1980||Mar 8, 1983||Medtronic, Inc.||Implantable cardioverter|
|US4384585||Mar 6, 1981||May 24, 1983||Medtronic, Inc.||Synchronous intracardiac cardioverter|
|US4577633||Mar 28, 1984||Mar 25, 1986||Medtronic, Inc.||Rate scanning demand pacemaker and method for treatment of tachycardia|
|US4587970||Jan 22, 1985||May 13, 1986||Telectronics N.V.||Tachycardia reversion pacer|
|US4726380||Oct 15, 1985||Feb 23, 1988||Telectronics, N.V.||Implantable cardiac pacer with discontinuous microprocessor, programmable antitachycardia mechanisms and patient data telemetry|
|US4727877||Aug 12, 1986||Mar 1, 1988||Medtronic, Inc.||Method and apparatus for low energy endocardial defibrillation|
|US4830006||Jun 17, 1986||May 16, 1989||Intermedics, Inc.||Implantable cardiac stimulator for detection and treatment of ventricular arrhythmias|
|US4880005||May 23, 1988||Nov 14, 1989||Intermedics, Inc.||Pacemaker for detecting and terminating a tachycardia|
|US4949719||Apr 26, 1989||Aug 21, 1990||Ventritex, Inc.||Method for cardiac defibrillation|
|US5105810 *||Jul 24, 1990||Apr 21, 1992||Telectronics Pacing Systems, Inc.||Implantable automatic and haemodynamically responsive cardioverting/defibrillating pacemaker with means for minimizing bradycardia support pacing voltages|
|US5117824||Nov 14, 1990||Jun 2, 1992||Medtronic, Inc.||Apparatus for monitoring electrical physiologic signals|
|US5161527 *||Feb 13, 1991||Nov 10, 1992||Telectronics Pacing Systems, Inc.||Apparatus and method for detecting abnormal cardiac rhythms in dual chamber arrhythmia control system|
|US5163427||Nov 14, 1990||Nov 17, 1992||Medtronic, Inc.||Apparatus for delivering single and multiple cardioversion and defibrillation pulses|
|US5188105||Nov 14, 1990||Feb 23, 1993||Medtronic, Inc.||Apparatus and method for treating a tachyarrhythmia|
|US5193550 *||Nov 30, 1990||Mar 16, 1993||Medtronic, Inc.||Method and apparatus for discriminating among normal and pathological tachyarrhythmias|
|US5205283 *||Jul 30, 1991||Apr 27, 1993||Medtronic, Inc.||Method and apparatus for tachyarrhythmia detection and treatment|
|US5261401||Nov 3, 1989||Nov 16, 1993||James Baker||Ambulatory cardiac diagnostic units having means for inhibiting pacemaker response|
|US5324326||Nov 25, 1991||Jun 28, 1994||Telectronics Pacing Systems, Inc.||Pressure sensing pacing lead|
|US5411524||Nov 2, 1993||May 2, 1995||Medtronic, Inc.||Method and apparatus for synchronization of atrial defibrillation pulses|
|US5535752||Feb 27, 1995||Jul 16, 1996||Medtronic, Inc.||Implantable capacitive absolute pressure and temperature monitor system|
|US5564434||Feb 27, 1995||Oct 15, 1996||Medtronic, Inc.||Implantable capacitive absolute pressure and temperature sensor|
|US5782876 *||Apr 15, 1996||Jul 21, 1998||Medtronic, Inc.||Method and apparatus using windows and an index value for identifying cardic arrhythmias|
|US5899927 *||Oct 17, 1997||May 4, 1999||Medtronic, Inc.||Detection of pressure waves transmitted through catheter/lead body|
|US6091988||Apr 30, 1998||Jul 18, 2000||Medtronic, Inc.||Apparatus for treating atrial tachyarrhythmias with synchronized shocks|
|US6095984 *||Apr 17, 1997||Aug 1, 2000||Seiko Epson Corporation||Arrhythmia detecting apparatus|
|US6185460 *||Jul 22, 1999||Feb 6, 2001||Medtronic, Inc.||Power consumption reduction in medical devices employing multiple digital signal processors|
|US6599242||Jul 19, 2000||Jul 29, 2003||Medtronic, Inc.||Method and apparatus for data compression of heart signals|
|US6873870||Apr 30, 2001||Mar 29, 2005||Medtronic, Inc.||Methods for adjusting cardiac detection criteria and implantable medical devices using same|
|US7024244 *||Apr 22, 2002||Apr 4, 2006||Medtronic, Inc.||Estimation of stroke volume cardiac output using an intracardiac pressure sensor|
|US20040167580 *||Oct 29, 2003||Aug 26, 2004||Brian Mann||Method for detecting, diagnosing, and treating cardiovascular disease|
|EP0317065A2||Oct 3, 1988||May 24, 1989||Todd J. Cohen||Hemodynamically responsive system for treating a malfunctioning heart|
|EP1410756A1||Oct 17, 2003||Apr 21, 2004||Pacesetter, Inc.||Hemodynamic analysis, in particular in a pacemaker|
|1||Kaye, Gerry C. et al., "Tachycardia Recognition and diagnosis from Changes in Right Atrial Pressure Waveform-A Feasibility Study," PACE, vol. 14, p. 1384-1392 (Sep. 1991).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8121682||Mar 23, 2010||Feb 21, 2012||Medtronic, Inc.||Combined hemodynamic and EGM-based arrhythmia detection|
|US8200329||Mar 23, 2010||Jun 12, 2012||Medtronic, Inc.||Combined hemodynamic and EGM-based arrhythmia detection|
|US9037223||Jan 10, 2013||May 19, 2015||The Regents Of The University Of Michigan||Atrial fibrillation classification using power measurement|
|US20100241182 *||Mar 23, 2010||Sep 23, 2010||Medtronic, Inc.||Combined hemodynamic and egm-based arrhythmia detection|
|U.S. Classification||600/515, 600/518|
|International Classification||A61N1/39, A61B5/04, A61B5/046, A61B5/042, A61N1/365, A61B5/00, A61N1/362, A61B5/0464, A61B5/0215|
|Cooperative Classification||A61N1/3956, A61N1/3622, A61B5/6882, A61N1/36564, A61B5/7257, A61B5/0464, A61B5/7264, A61B5/0031, A61B5/0215, A61B5/046, A61B5/0422|
|European Classification||A61B5/68D3D, A61B5/72K12, A61B5/0215, A61B5/0464, A61N1/39M, A61N1/365B9, A61N1/362A2|
|Oct 1, 2004||AS||Assignment|
Owner name: MEDTRONIC, INC., MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HETTRICK, DOUGLAS A.;EULER, DAVID E.;BROWN, MARK L.;REEL/FRAME:015207/0184;SIGNING DATES FROM 20040707 TO 20040728
|Nov 22, 2010||FPAY||Fee payment|
Year of fee payment: 4
|Dec 19, 2014||FPAY||Fee payment|
Year of fee payment: 8